Expression of p16 in serous ovarian neoplasms

Eur J Gynaecol Oncol. 2010;31(3):312-4.


Purpose: We aimed to examine p16 protein expression in ovarian serous neoplasms along with normal ovarian tissues.

Materials and methods: P16 expression was immunhistochemically evaluated in 86 ovarian serous neoplasms (21 cystadenomas, 20 borderline tumors and 45 carcinomas) and 21 non-neoplastic ovarian tissue. The results were also compared with histopathological grade in serous adenocarcinomas.

Results: P16 expression rates for benign, borderline ovarian tumors and ovarian cancer were 14.2%, 85% and 86.6%, respectively. It was significantly higher in carcinomas (p < 0.001) and borderline tumors (p < 0.001) compared to cystadenomas. No immunoreactivity was found in the non-neoplastic ovarian surface epithelial cells. The percentage of p16 expression did not change significantly with histological grade in carcinomas.

Conclusion: P16 expression is strong and widespread involving most tumor cells in serous papillary ovarian carcinomas, and is probably an early event.

MeSH terms

  • Cyclin-Dependent Kinase Inhibitor p16
  • Cystadenocarcinoma, Serous / chemistry*
  • Cystadenocarcinoma, Serous / pathology
  • Female
  • Humans
  • Immunohistochemistry
  • Neoplasm Proteins / analysis*
  • Ovarian Neoplasms / chemistry*
  • Ovarian Neoplasms / pathology


  • CDKN2A protein, human
  • Cyclin-Dependent Kinase Inhibitor p16
  • Neoplasm Proteins